Evidence map›Paper›PMID 26231396›Full record

ArticleRespiratory research2015

Building a better neonatal mouse model to understand infant respiratory syncytial virus disease.

Dahui You, David T Siefker, Bishwas Shrestha, Jordy Saravia, Stephania A Cormier

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Environmental science & technology · 2022
    Article
  7. IL-1β Promotes Expansion of IL-33American journal of respiratory cell and molecular biology · 2022
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Inhibition of NF-Journal of immunology research · 2021
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Dahui YouDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA.
David T SiefkerDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA.
Bishwas ShresthaDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA.
Jordy SaraviaDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA.
Stephania A CormierDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA. scormier@uthsc.edu.
University of Tennessee Health Science Center · USLe Bonheur Children's Hospital · US

Funding

Role of microbiota in increased influenza severity due to particulate matter exposureP42ES013648 · NIEHS · LOUISIANA STATE UNIV A&M COL BATON ROUGE · PI SPRUNGER, PHILLIP · 2009 to 2024
$27.6M
The Role of IL4R Alpha in Neonatal RSV ImmunopathologyR01AI090059 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI CORMIER, STEPHANIA A · 2011 to 2025
$6.7M
Combustion Generated PM0.1 and Predisposition to AsthmaR01ES015050 · NIEHS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI CORMIER, STEPHANIA A · 2006 to 2022
$4.6M
NIAID NIH HHS R01 AI090059NIAID NIH HHS R01AI090059NIEHS NIH HHS P42 ES013648NIEHS NIH HHS P42ES013648NIEHS NIH HHS R01 ES015050NIEHS NIH HHS R01ES015050
6 · The paper itself

Abstract

backgroundRespiratory syncytial virus (RSV) is the number one cause of lower respiratory tract infection in infants; and severe RSV infection in infants is associated with asthma development. Today, there are still no vaccines or specific antiviral therapies against RSV. The mechanisms of RSV pathogenesis in infants remain elusive. This is partly due to the fact that the largely-used mouse model is semi-permissive for RSV. The present study sought to determine if a better neonatal mouse model of RSV infection could be obtained using a chimeric virus in which the F protein of A2 strain was replaced with the F protein from the line 19 clinical isolate (rA2-19F).

methodsFive-day-old pups were infected with the standard laboratory strain A2 or rA2-19F and various immunological and pathophysiological parameters were measured at different time points post infection, including lung histology, bronchoalveolar lavage fluid (BALF) cellularity and cytokines, pulmonary T cell profile, and lung viral load. A cohort of infected neonates were allowed to mature to adulthood and reinfected. Pulmonary function, BALF cellularity and cytokines, and T cell profiles were measured at 6 days post reinfection.

resultsThe rA2-19F strain in neonatal mice caused substantial lung pathology including interstitial inflammation and airway mucus production, while A2 caused minimal inflammation and mucus production. Pulmonary inflammation was characterized by enhanced Th2 and reduced Th1 and effector CD8(+) T cells compared to A2. As with primary infection, reinfection with rA2-19F induced similar but exaggerated Th2 and reduced Th1 and effector CD8(+) T cell responses. These immune responses were associated with increased airway hyperreactivity, mucus hyperproduction and eosinophilia that was greater than that observed with A2 reinfection. Pulmonary viral load during primary infection was higher with rA2-19F than A2.

conclusionsTherefore, rA2-19F caused enhanced lung pathology and Th2 and reduced effector CD8(+) T cell responses compared to A2 during initial infection in neonatal mice and these responses were exacerbated upon reinfection. The exact mechanism is unknown but appears to be associated with increased pulmonary viral load in rA2-19F vs. A2 infected neonatal lungs. The rA2-19F strain represents a better neonatal mouse model of RSV infection.

Indexed as

ComprehensionDisease Models, AnimalRespiratory Syncytial VirusesAnimalsAnimals, NewbornChlorocebus aethiopsFemaleHumansMiceMice, Inbred BALB CRespiratory Syncytial Virus InfectionsVero Cells

Identifiers

PMID26231396
PMCPMC4531813
OpenAlexW2159424092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.